Clinical Scorecard: The Impact of Systematic Biopsy in Identifying Clinically Significant Prostate Cancer During Primary MRI-Guided Biopsy: Insights from a High-Volume Single-Center Analysis

At a Glance

Key Highlights

• Combined biopsy (CB) approach (TB + SB) significantly increases detection rates of clinically significant prostate cancer compared to TB or SB alone.
• Systematic biopsy complements MRI-targeted biopsy by detecting additional csPCA missed due to MRI invisibility or targeting errors.
• Prostate cancer detection rates correlate positively with abnormal DRE, suspicious transrectal ultrasound, elevated PSA density, and smaller prostate volume.

Guideline-Based Recommendations

Diagnosis

• Use multiparametric MRI with PI-RADS v2.1 scoring to guide biopsy decisions.
• Perform combined biopsy (MRI-targeted plus systematic biopsy) during initial prostate cancer evaluation to maximize detection of csPCA.

Management

• Tailor disease management based on improved tumor grading and extent from combined biopsy results.
• Consider PSA density, prostate volume, DRE, and ultrasound findings to stratify cancer detection risk.

Monitoring & Follow-up

• Monitor biopsy outcomes and histopathology results to assess tumor grading accuracy and guide treatment planning.
• Evaluate patients for biopsy-related complications such as urinary tract infections.

Risks

• MRI-only biopsy pathways may miss a significant proportion of clinically significant prostate cancers.
• Systematic biopsy may detect more nonsignificant PCA, potentially leading to overdiagnosis.
• Biopsy procedures carry a low but present risk of urinary tract infection (~0.8% in this cohort).

Patient & Prescribing Data

Biopsy-naïve men with suspicious PSA, abnormal DRE, or abnormal transrectal ultrasound findings and PI-RADS ≥ 3 lesions

Combined biopsy approach improves detection of clinically significant prostate cancer, enabling more accurate tumor grading and personalized management.

Clinical Best Practices

• Perform combined MRI-targeted and systematic biopsy in biopsy-naïve men with PI-RADS ≥ 3 lesions to optimize csPCA detection.
• Use software-assisted fusion biopsy techniques and standardized templates to ensure comprehensive sampling.
• Incorporate clinical parameters such as PSA density, prostate volume, DRE, and ultrasound findings to guide biopsy strategy and interpret results.
• Ensure biopsy procedures are performed by experienced urologists with adequate volume to maintain proficiency.
• Apply antibiotic prophylaxis, rectal cleansing, and local anesthesia to minimize procedural complications.

References

• European Association of Urology Guidelines on Prostate Cancer
• PI-RADS v2.1 Prostate Imaging Reporting and Data System